MEBANAZINE


Synonyms	Actamol Mebanazine
Status
Molecule Category	UNKNOWN
UNII	Z5R55CJ4CG


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HHRZAEJMHSGZNP-UHFFFAOYSA-N
Smiles	CC(NN)c1ccccc1
InChI	InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H12N2
Molecular Weight	136.2
AlogP	1.21
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	38.05
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	10.0

Bioactivity

Mechanism of Action	Action	Reference
Monoamine oxidase inhibitor	INHIBITOR	PubMed PubMed PubMed PubMed


Protein: Monoamine oxidase Description: Amine oxidase [flavin-containing] A Organism : Homo sapiens P21397 ENSG00000189221











Protein: Monoamine oxidase Description: Amine oxidase [flavin-containing] B Organism : Homo sapiens P27338 ENSG00000069535

Cross References

Resources	Reference
ChEBI	134728
ChEMBL	CHEMBL1909283
DrugBank	DB09248
DrugCentral	4865
FDA SRS	Z5R55CJ4CG
PubChem	6179
SureChEMBL	SCHEMBL182461

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).